Natera, Inc. (NASDAQ:NTRA) Insider Sells $86,527.06 in Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 929 shares of the business’s stock in a transaction on Monday, April 29th. The stock was sold at an average price of $93.14, for a total transaction of $86,527.06. Following the sale, the insider now owns 110,748 shares in the company, valued at $10,315,068.72. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Natera Stock Performance

Shares of NASDAQ NTRA opened at $96.98 on Friday. The company has a 50-day simple moving average of $90.56 and a 200-day simple moving average of $69.29. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96. The company has a market cap of $11.86 billion, a PE ratio of -25.59 and a beta of 1.38. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $98.82.

Natera (NASDAQ:NTRA) last released its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.09. The firm had revenue of $311.11 million during the quarter, compared to analysts’ expectations of $300.38 million. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. On average, equities analysts anticipate that Natera, Inc. will post -2.35 earnings per share for the current year.

Institutional Investors Weigh In On Natera

A number of hedge funds and other institutional investors have recently made changes to their positions in NTRA. FDx Advisors Inc. lifted its position in Natera by 17.1% during the first quarter. FDx Advisors Inc. now owns 5,109 shares of the medical research company’s stock worth $467,000 after buying an additional 747 shares during the period. Chevy Chase Trust Holdings LLC purchased a new position in shares of Natera during the 1st quarter worth about $14,467,000. GSA Capital Partners LLP lifted its holdings in shares of Natera by 41.8% during the 1st quarter. GSA Capital Partners LLP now owns 28,222 shares of the medical research company’s stock worth $2,581,000 after acquiring an additional 8,319 shares during the period. RiverPark Advisors LLC boosted its position in shares of Natera by 581.8% in the first quarter. RiverPark Advisors LLC now owns 2,952 shares of the medical research company’s stock worth $270,000 after acquiring an additional 2,519 shares during the last quarter. Finally, Nikko Asset Management Americas Inc. purchased a new stake in Natera in the first quarter valued at approximately $33,938,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

NTRA has been the subject of a number of research reports. Piper Sandler lifted their price target on shares of Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. Raymond James downgraded Natera from a “strong-buy” rating to an “outperform” rating and boosted their target price for the stock from $68.00 to $85.00 in a research report on Tuesday, February 20th. The Goldman Sachs Group raised their price target on Natera from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, April 15th. Canaccord Genuity Group lifted their price target on Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. Finally, Craig Hallum started coverage on shares of Natera in a research note on Monday, April 8th. They issued a “buy” rating and a $117.00 price objective on the stock. One research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, Natera currently has an average rating of “Moderate Buy” and a consensus price target of $86.40.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.